keyword
MENU ▼
Read by QxMD icon Read
search

Estrogen Receptor Myeloid derived suppressor cells Breast Cancer

keyword
https://read.qxmd.com/read/30956772/estrogen-stimulates-female-cancer-progression-by-inducing-myeloid-derived-suppressive-cells-investigations-on-pregnant-and-non-pregnant-experimental-models
#1
Katsumi Kozasa, Seiji Mabuchi, Yuri Matsumoto, Hiromasa Kuroda, Eriko Yokoi, Naoko Komura, Mahiru Kawano, Ryoko Takahashi, Tomoyuki Sasano, Kotaro Shimura, Michiko Kodama, Kae Hashimoto, Kenjiro Sawada, Kazunori Nagasaka, Tadashi Kimura
Objective: To investigate the clinical implications of 17β-estradiol (E2) in estrogen receptor α (ERα)-negative female cancer progression as well as the underlying biological mechanisms. Methods: Clinical data from 306 locally-advanced cervical cancer (stage IIB-IVA) patients were analyzed in order to investigate the relationships between age, serum E2 levels, and treatment outcomes. Clinical samples, ERα-negative cervical and breast cancer cell lines, and mouse xenograft models of cervical and breast cancers were employed in order to elucidate the mechanisms responsible for the E2- and pregnancy-mediated progression of cervical and breast cancers, with a focus on the role of myeloid-derived suppressor cells (MDSC)...
March 8, 2019: Oncotarget
https://read.qxmd.com/read/30546090/type-i-interferon-irf7-axis-instigates-chemotherapy-induced-immunological-dormancy-in-breast-cancer
#2
Qiang Lan, Sanam Peyvandi, Nathalie Duffey, Yu-Ting Huang, David Barras, Werner Held, François Richard, Mauro Delorenzi, Christos Sotiriou, Christine Desmedt, Girieca Lorusso, Curzio Rüegg
Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER- ) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental evidence that ER- breast cancer cells that survived high-dose Doxorubicin and Methotrexate based chemotherapies elicit a state of immunological dormancy...
December 13, 2018: Oncogene
https://read.qxmd.com/read/30349367/predicting-the-response-to-neoadjuvant-therapy-for-early-stage-breast-cancer-tumor-blood-and-imaging-related-biomarkers
#3
REVIEW
Wenyong Tan, Ming Yang, Hongli Yang, Fangbin Zhou, Weixi Shen
Neoadjuvant therapy (NAT) has been used increasingly in patients with locally advanced or early-stage breast cancer. However, the accurate evaluation and prediction of response to NAT remain the great challenge. Biomarkers could prove useful to identify responders or nonresponders, or even to distinguish between early and delayed responses. These biomarkers could include markers from the tumor itself, such as versatile proteins, genes, and ribonucleic acids, various biological factors or peripheral blood cells, and clinical and pathological features...
2018: Cancer Management and Research
https://read.qxmd.com/read/27996037/estrogen-induced-sdf-1%C3%AE-production-promotes-the-progression-of-er-negative-breast-cancer-via-the-accumulation-of-mdscs-in-the-tumor-microenvironment
#4
Liquan Ouyang, Weilong Chang, Bin Fang, Jieting Qin, Xincai Qu, Fanjun Cheng
Estrogen plays a role in the processes of tumorigenesis, metastasis, and drug resistance in estrogen receptor (ER)-positive breast cancer (BC). Whether estrogen contributes to ER-negative BC is unclear. Here, we aimed to investigate whether estrogen could stimulate the secretion of stromal-derived factor-1 (SDF-1α) by cancer-associated fibroblasts (CAFs) to promote the progression of ER-negative BC. We transplanted ER-negative BC cells into ovariectomized mice, which was followed by continuous injection of estrogen, and found that estrogen promoted the tumorigenesis of BC...
December 20, 2016: Scientific Reports
https://read.qxmd.com/read/22760522/dipyridamole-prevents-triple-negative-breast-cancer-progression
#5
Daniela Spano, Jean-Claude Marshall, Natascia Marino, Daniela De Martino, Alessia Romano, Maria Nunzia Scoppettuolo, Anna Maria Bello, Valeria Di Dato, Luigi Navas, Gennaro De Vita, Chiara Medaglia, Patricia S Steeg, Massimo Zollo
Dipyridamole is a widely prescribed drug in ischemic disorders, and it is here investigated for potential clinical use as a new treatment for breast cancer. Xenograft mice bearing triple-negative breast cancer 4T1-Luc or MDA-MB-231T cells were generated. In these in vivo models, dipyridamole effects were investigated for primary tumor growth, metastasis formation, cell cycle, apoptosis, signaling pathways, immune cell infiltration, and serum inflammatory cytokines levels. Dipyridamole significantly reduced primary tumor growth and metastasis formation by intraperitoneal administration...
January 2013: Clinical & Experimental Metastasis
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"